Go Pro
→ AI Panic: Sell now or wait? (From TradeSmith) (Ad)tc pixel Free PTPI Stock Alerts

Petros Pharmaceuticals (PTPI) Competitors

Petros Pharmaceuticals logo
$0.0050 +0.00 (+25.00%)
As of 02:31 PM Eastern
Compare

PTPI vs. CNSP, IMCC, PRPH, NKGN, and SRNE

Should you buy Petros Pharmaceuticals stock or one of its competitors? Petros Pharmaceuticals's main competitors and comparable companies include CNS Pharmaceuticals (CNSP), IM Cannabis (IMCC), ProPhase Labs (PRPH), NKGen Biotech (NKGN), and Sorrento Therapeutics (SRNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.03-$8.16M-$0.36N/A
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
CNS Pharmaceuticals Neutral

Petros Pharmaceuticals has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
CNS Pharmaceuticals N/A -204.25%-141.87%

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to IM Cannabis?

IM Cannabis (NASDAQ:IMCC) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

IM Cannabis has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Petros Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. Petros Pharmaceuticals' return on equity of -78.22% beat IM Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
IM Cannabis-39.62% -585.96% -58.32%
Petros Pharmaceuticals N/A -78.22%-23.50%

7.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

IM Cannabis has higher revenue and earnings than Petros Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IM Cannabis$39.17M0.02-$8.10M-$60.66N/A
Petros Pharmaceuticals$5.11M0.03-$8.16M-$0.36N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, IM Cannabis had 14 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 14 mentions for IM Cannabis and 0 mentions for Petros Pharmaceuticals. IM Cannabis' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
IM Cannabis Neutral
Petros Pharmaceuticals Neutral

Summary

Petros Pharmaceuticals beats IM Cannabis on 8 of the 13 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to ProPhase Labs?

Petros Pharmaceuticals (NASDAQ:PTPI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Petros Pharmaceuticals has higher revenue and earnings than ProPhase Labs. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.03-$8.16M-$0.36N/A
ProPhase Labs$5.06M0.03-$53.36M-$2.25N/A

In the previous week, ProPhase Labs had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat ProPhase Labs' score of -0.18 indicating that Petros Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
ProPhase Labs Neutral

Petros Pharmaceuticals has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Petros Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Petros Pharmaceuticals' return on equity of -78.22% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
ProPhase Labs -825.01%-482.05%-88.90%

Summary

Petros Pharmaceuticals beats ProPhase Labs on 11 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Petros Pharmaceuticals Neutral

Petros Pharmaceuticals has higher revenue and earnings than NKGen Biotech. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Petros Pharmaceuticals$5.11M0.03-$8.16M-$0.36N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NKGen Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Petros Pharmaceuticals N/A -78.22%-23.50%

Summary

Petros Pharmaceuticals beats NKGen Biotech on 7 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Sorrento Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Sorrento Therapeutics Neutral
Petros Pharmaceuticals Neutral

Sorrento Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Sorrento TherapeuticsN/A N/A N/A
Petros Pharmaceuticals N/A -78.22%-23.50%

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Petros Pharmaceuticals has lower revenue, but higher earnings than Sorrento Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sorrento Therapeutics$60.32M0.01-$572.84M-$0.17N/A
Petros Pharmaceuticals$5.11M0.03-$8.16M-$0.36N/A

Sorrento Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Summary

Petros Pharmaceuticals beats Sorrento Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTPI vs. The Competition

Export
MetricPetros PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$156K$12.52B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.7325.76
Price / Sales0.03850.62679.5697.70
Price / CashN/A88.6477.8052.76
Price / Book0.0010.6910.526.34
Net Income-$8.16M$2.83B$3.49B$360.00M
7 Day PerformanceN/A-0.68%-1.10%-0.13%
1 Month PerformanceN/A-1.13%-3.42%-3.45%
1 Year PerformanceN/A2.15%15.10%5.46%

Petros Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTPI
Petros Pharmaceuticals
N/A$0.01
+25.0%		N/A-84.4%$156K$5.11MN/A20
CNSP
CNS Pharmaceuticals
0.5517 of 5 stars		$5.22
-8.4%		N/A-36.0%$8.33MN/AN/A5
IMCC
IM Cannabis
0.3009 of 5 stars		$1.63
flat		N/A-94.8%$340K$39.17MN/A340
PRPH
ProPhase Labs
0.2125 of 5 stars		$0.02
+6.0%		N/A-99.7%$288K$5.06MN/A130
NKGN
NKGen Biotech
N/A$0.00
flat		N/A-89.1%$274KN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...
Behind the Markets | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel